OTC : BIOGF

Biocartis Group N.V.

$0.66 USD

-$3.84 (-85.33%)

Volume
3.3K
Average Volume
55
Market Capitalization
$65.41M
P/E Ratio
-0.27
Dividend Yield
0.00%
Price Target
Year High
$0.66
Year Low
$0.66
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$1.65
Company Overview

OTC

Roger Moody

Medical - Diagnostics & Research

Healthcare

BIOGF

526

BE

USD

https://www.biocartis.com

32 1 563 20 00

N/A

N/A

Liquidity Metrics

-4.04

1.65

1.20

0.59

0.00

Sales & Valuation

$57.48M

0.47

-0.58

-0.58

-0.77

Profitability

-$1.08

-$65.38M

-113.74%

-114.16%

203.74%

-57.21%

P/E Metrics

-0.27

0.00

0.00

Analyst Price Target & Rating

N/A

0/5

0 Analysts

%

Financial Health Scores

-7.06

2/9

$37.22M

$112.98M

$166.97M

-$85.65M

Key Metrics (TTM)

$124.67M

2.17

-2.81

1.65

203.74%

-50.72%

-372.36%

-171.80%

201 days

Company Executives
Name Title
Roger Moody Chief Executive Officer
Erwin Sablon Head of R&D and Alliance Management
George A. Cardoza Chief Financial Officer & Head of Service Delivery
Piet Houwen Chief Operating Officer
Reginald Van Genechten Head of Manufacturing & Supply Chain
Sarah Baudenelle Head of Operations & On-Market Product Support
Susy Spruyt Head of People & Organization
Renate Degrave Head of IR & Corporation Communications
Geert Maertens Chairman of Scientific Advisory Board & Chief Scientific Officer
Benoit Devogelaere Chief Technology Officer
Erik Vossenaar Senior Vice-President of Corporate Development and Strategy
W. Michael Korn Chief Medical & Scientific Officer
Poll Results

No votes yet today — be the first to share your view!

About Biocartis Group N.V. (OTC:BIOGF) Stock

Biocartis Group N.V. is a molecular diagnostics firm dedicated to advancing clinical practice through innovative diagnostic solutions. These offerings aim to benefit patients, clinicians, healthcare payers, and the wider healthcare industry, with a particular emphasis on the field of oncology. Central to their product portfolio is the proprietary Idylla platform, a real-time polymerase chain reaction (PCR) system. This cutting-edge technology delivers vital molecular information, which is instrumental in both selecting appropriate treatments and continuously monitoring their effectiveness. The company provides a diverse array of Idylla tests, including mutation analyses for oncology biomarkers such as BRAF, KRAS, MSI, EGFR, and NRAS-BRAF. Beyond cancer diagnostics, they also offer panels f ... or infectious diseases, specifically Idylla SARS-CoV-2/Flu/RSV and standalone SARS-CoV-2 tests. Additionally, their SeptiCyte RAPID test offers quick assessment of host response. For research purposes, Biocartis supplies various assays for detecting mutations, including those for MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R. Biocartis actively engages in strategic collaborations. They have partnered with Amgen to evaluate the Idylla RAS testing capabilities, aiming for rapid, decentralized diagnostics and faster access to crucial RAS biomarker data via the Idylla platform. Another collaboration with Bristol-Myers Squibb Company focuses on the regulatory approval and application of the Idylla MSI test in conjunction with immuno-oncology therapies. Furthermore, Biocartis holds a licensing, development, and commercialization agreement with GeneproDx for integrating the novel ThyroidPrint genomic test onto the Idylla platform. Founded in 2007, Biocartis Group N.V. operates from its headquarters located in Mechelen, Belgium.

Frequently Asked Questions

What is the current Biocartis Group N.V. (BIOGF) stock price?

Biocartis Group N.V.(OTC:BIOGF) stock price is $0.66 in the last trading session. During the trading session, BIOGF stock reached the peak price of $0.66 while $0.66 was the lowest point it dropped to. The percentage change in BIOGF stock occurred in the recent session was --85.33% while the dollar amount for the price change in BIOGF stock was -$3.84.

BIOGF's industry and sector of operation?

The OTC listed BIOGF is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.

Who are the executives of BIOGF?

Roger Moody | Chief Executive Officer
Erwin Sablon | Head of R&D and Alliance Management
George A. Cardoza | Chief Financial Officer & Head of Service Delivery
Piet Houwen | Chief Operating Officer
Reginald Van Genechten | Head of Manufacturing & Supply Chain

How many employees does BIOGF have?

Number of BIOGF employees currently stands at 526. BIOGF operates from Generaal de Wittelaan 11 B, Mechelen, None 2800, BE.

Link for BIOGF official website?

Official Website of BIOGF is: https://www.biocartis.com

How do I contact BIOGF?

BIOGF could be contacted at phone #32 1 563 20 00 and can also be accessed through its website. BIOGF operates from Generaal de Wittelaan 11 B, Mechelen, None 2800, BE.

How many shares of BIOGF are traded daily?

The average number of BIOGF shares traded daily for last 3 months was 55.

What is the market cap of BIOGF currently?

The market value of BIOGF currently stands at $65.41M with its latest stock price at $0.66